sustained fat loss depends on starting weight, metabolic health, dose discipline, protein intake, and training
Curcumin should be used to inhibit inflammatory pathways
Health Canada has issued multiple public advisories since 2023 on unauthorized injectable peptide products, with BPC-157 named explicitly on the list of seized substances in actions against Canlab Research, Prime Research, and other vendors

Based on current clinical trial data and the medications mechanism of action, retatrutide may be particularly beneficial for: Individuals with significant obesity (BMI 30+) who need substantial weight loss People with type 2 diabetes seeking both glycemic control and weight reduction Patients with non-alcoholic fatty liver disease the liver fat reduction data is among the most impressive for any medication Those who have plateaued on semaglutide or tirzepatide the additional glucagon pathway may overcome metabolic adaptation Individuals with insulin resistance or metabolic syndrome the comprehensive metabolic effects address multiple aspects of metabolic dysfunction Retatrutide may not be appropriate for: Individuals with a history of medullary thyroid carcinoma or MEN2 syndrome Patients with severe gastrointestinal disorders Pregnant or breastfeeding women Those with a history of pancreatitis Individuals with certain endocrine or thyroid conditions A comprehensive medical evaluation including laboratory testing is essential before starting any weight loss medication

David found the candor reassuring rather than discouraging
While GLP-1 and Wegovy accomplish similar goals, they do so with different rates of effectiveness